Wave crash­es — again — as 2 more drugs go down to de­feat, this time for Hunt­ing­ton's

Just sev­en days ago Roche threw in the tow­el on their an­ti­sense drug for Hunt­ing­ton’s. Now we’re learn­ing that a close­ly-watched an­ti­sense oligonu­cleotide pro­gram in the hands of Wave Life Sci­ences $WVE crashed in an ear­ly-stage study — wip­ing out two ex­per­i­men­tal drug can­di­dates and forc­ing the biotech to turn to a back-up ap­proach while watch­ing shares crater.

WVE-120102 failed to sep­a­rate from place­bo in im­pact on mu­tant Hunt­ingtin pro­tein at any of the dos­es giv­en to Hunt­ing­ton’s pa­tients. And a sep­a­rate, small­er study showed on­ly an in­con­sis­tent hit on mHTT that in­di­cat­ed they were on a one-way track to fail­ure with the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER